Aytu BioPharma Reports Fiscal 2026 Financial Results
Aytu BioPharma reported a 6.4% increase in Q4 net revenue to $16.1 million, driven by the ADDVANCE gel product. The company highlighted the commercial launch of its EXXUA product, recording revenue of $6.6 million for the fiscal year.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed